drugset
drugset / Trial / NCT03574415

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean

NCT03574415 ↗

Phase 1 Completed 80 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindBasic science

Summary

To evaluate the safety and tolerability of single and multiple ascending oral doses of DWP14012 in healthy Japanese, Caucasian and Korean subjects

Timeline

Start
2018-11-01
Primary completion
2019-01-18
Completion
2019-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — Oral

Indications

No indication recorded.